Deals & Cases
Listing of ObsEva SA on SIX Swiss Exchange
ObsEva SA, a NASDAQ-listed clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy confirmed on July 6, 2018 its intention to list its shares on SIX Swiss Exchange.
The transaction is structured as a direct listing, with no offering of new shares. ObsEva's shares are expected to begin trading on SIX Swiss Exchange on July 13, 2018, and will continue to be listed on the NASDAQ. Lenz & Staehelin advises ObsEva in connection with the listing of its shares on SIX Swiss Exchange and is also acting as listing agent.
The Lenz & Staehelin team is led by partner Jacques Iffland (Corporate and M&A and Capital Markets) and includes associates Ariel Ben Hattar and Danusha Nacht (both Corporate and M&A and Capital Markets).